180 Life Ownership
ATNF Stock | USD 2.19 0.01 0.45% |
Shares in Circulation | First Issued 2017-06-30 | Previous Quarter 919.1 K | Current Value 980.6 K | Avarage Shares Outstanding 1.1 M | Quarterly Volatility 5.2 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
180 |
180 Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 1.16. Some equities with similar Price to Book (P/B) outperform the market in the long run. 180 Life Sciences recorded earning per share (EPS) of 7.98. The entity had not issued any dividends in recent years. The firm had 1:19 split on the 28th of February 2024. 1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company was incorporated in 2016 and is headquartered in Palo Alto, California. 180 Life operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. For more info on 180 Life Sciences please contact the company at 650 507 0669 or go to https://180lifesciences.com.Besides selling stocks to institutional investors, 180 Life also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different 180 Life's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align 180 Life's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
180 Life Quarterly Liabilities And Stockholders Equity |
|
180 Life Insider Trades History
About 4.0% of 180 Life Sciences are currently held by insiders. Unlike 180 Life's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against 180 Life's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of 180 Life's insider trades
180 Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as 180 Life is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading 180 Life Sciences backward and forwards among themselves. 180 Life's institutional investor refers to the entity that pools money to purchase 180 Life's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Tower Research Capital Llc | 2024-06-30 | 6.3 K | Blackrock Inc | 2024-06-30 | 772 | Bank Of America Corp | 2024-06-30 | 12.0 | Royal Bank Of Canada | 2024-06-30 | 11.0 | Qube Research & Technologies | 2024-06-30 | 2.0 | Semmax Financial Advisors Inc. | 2024-06-30 | 1.0 | Jpmorgan Chase & Co | 2024-06-30 | 1.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Ifp Advisors, Llc | 2024-06-30 | 0.0 | Charles Schwab Investment Management Inc | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 |
180 Life Sciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific 180 Life insiders, such as employees or executives, is commonly permitted as long as it does not rely on 180 Life's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases 180 Life insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
180 Life Outstanding Bonds
180 Life issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. 180 Life Sciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most 180 bonds can be classified according to their maturity, which is the date when 180 Life Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
US68233JBV52 Corp BondUS68233JBV52 | View | |
US68233JBU79 Corp BondUS68233JBU79 | View | |
US68233JBR41 Corp BondUS68233JBR41 | View | |
US68233JBP84 Corp BondUS68233JBP84 | View | |
ONCOR ELEC DELIVERY Corp BondUS68233JBG85 | View | |
ONCOR ELEC DELIVERY Corp BondUS68233JBH68 | View | |
US68233JBD54 Corp BondUS68233JBD54 | View |
180 Life Corporate Filings
S1 | 15th of November 2024 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
12th of November 2024 Other Reports | ViewVerify | |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether 180 Life Sciences is a strong investment it is important to analyze 180 Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 180 Life's future performance. For an informed investment choice regarding 180 Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in 180 Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 180 Life. If investors know 180 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 180 Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 7.98 | Return On Assets (0.64) | Return On Equity (3.99) |
The market value of 180 Life Sciences is measured differently than its book value, which is the value of 180 that is recorded on the company's balance sheet. Investors also form their own opinion of 180 Life's value that differs from its market value or its book value, called intrinsic value, which is 180 Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 180 Life's market value can be influenced by many factors that don't directly affect 180 Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 180 Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if 180 Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 180 Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.